Delta Capita Launches Elaris OTC, Powered by Fragmos Chain, to Revolutionise OTC Derivatives Post-Trade Globally

Delta Capita has launched Elaris OTC, a post-trade solution for OTC derivatives, powered by Fragmos Chain. The Delta Capita Elaris OTC platform focuses on automation and improved operational workflows.

The OTC derivatives market, valued at approximately $700 trillion according to the Bank for International Settlements (BIS), remains fragmented, with an estimated 20% of trades still confirmed and settled manually. Elaris OTC addresses this inefficiency by offering a fully digitised, automated, interoperable solution.

Powered by Fragmos Chain, Elaris OTC is a technology platform that enables seamless and fully automated matching of OTC derivatives trades and lifecycle events between market participants, and achieves interoperability by translating native client messaging formats into the Common Domain Model (CDM) standard. This allows institutions to reduce operational costs and risk significantly while supporting all asset classes and lifecycle events. 

Crucially, Elaris OTC is more than just a platform: it can be combined with Delta Capita’s global OTC confirmation and settlement services to extend automation beyond platform participants. This combination enables users to capture and manage interactions with all counterparties – whether or not they use the platform, and leverages Delta Capita’s established service model to deliver straight-through processing and control across the full spectrum of post-trade activity.

Mark Aldous, Global Head of Capital Markets Managed Services at Delta Capita, stated:
“This end-to-end offering brings together best-in-class technology and proven operational capabilities. Fully digital, CDM-aligned, and scalable, Elaris OTC sets a new standard for the industry.”

Daniel Ivanier, CEO of Fragmos Chain, commented: “Our technology now powers a truly global post-trade solution. By integrating with Delta Capita’s services, Elaris OTC delivers immediate impact and accelerates adoption for both sell side and buy side firms.” 

This launch builds on Delta Capita’s momentum in capital markets innovation, following recent strategic acquisitions and advancements in capital markets technology. It reinforces Delta Capita’s role as a trusted partner to global financial institutions seeking scalable, efficient solutions in an ever-evolving market. 

The Delta Capita Elaris OTC solution reflects ongoing efforts to simplify derivatives operations through technology partnerships. Elaris OTC follows Delta Capita’s multi-year agreement to deliver post-trade OTC derivative services globally for HSBC.